Tag: Cancer: Prostate
Apalutamide Safe for Men With Prostate Cancer on Active Surveillance
Greater number of negative posttreatment biopsies seen among men with higher baseline genomic risk score
MRI-Guided Radiotherapy Bests CT Guidance for Prostate Cancer
Benefits seen for genitourinary and gastrointestinal toxic effects
Social Determinants of Health Affect Racial Disparity in Prostate Cancer Mortality
When accounting for social determinants of health, Black men have significantly lower prostate cancer-specific mortality than White men
Low-Value Prostate Cancer Screening Common in Primary Care
Providers who order several tests are more likely to order low-value prostate cancer screening
Per-Patient Costs of Metastatic Prostate Cancer Estimated at $31,427
Increase in annual attributable costs observed over time, from $28,311 in 2007-2013 to $37,055 in 2014-2017
On-Site Genetic Testing for Prostate Cancer Increases Patient Compliance
Implementation of on-site guideline-based genetic testing for prostate cancer patients increased compliance from 33.3 to 98.7 percent
Trends in Genitourinary Cancers Examined in the United States
Among non-Hispanic Whites, highest incidence rates seen in Northeast for bladder cancer, Appalachia for kidney cancer
MRI-Targeted Biopsy Beneficial for Men With Elevated PSA
Fewer men in experimental group received diagnosis of clinically insignificant prostate cancer
Melanoma Diagnosis Linked to Increased Risk of Prostate Cancer
More than twofold increased risk of prostate cancer seen for men with first melanoma diagnosed 10 to 15 years before study recruitment
Treatment Without ADT Delays Initiation of Systemic Therapy in Prostate Cancer
Metastasis-directed therapy can delay initiation of systemic therapy in patients with solitary oligorecurrent metastatic lesion
